16,900€
3,05%
Echtzeit-Aktienkurs TERUMO CORP.
Bid:
Ask:
Echtzeit-Chart der TERUMO CORP. Aktie
Fundamentaldaten der TERUMO CORP. Aktie
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 6,38 Mrd. | 974,04 Mio. | 735,63 Mio. | 0,49 | 0,60% | 34,21 | 3,94 |
| 2023 [USD] | 6,05 Mrd. | 855,73 Mio. | 659,14 Mio. | 0,44 | 0,61% | 38,50 | 4,16 |
| 2022 [USD] | 6,26 Mrd. | 1,02 Mrd. | 790,34 Mio. | 0,52 | 0,58% | 32,31 | 4,08 |
| 2021 [USD] | 5,79 Mrd. | 921,92 Mio. | 728,54 Mio. | 0,48 | 0,56% | 35,06 | 4,41 |
| 2020 [USD] | 5,78 Mrd. | 979,22 Mio. | 783,71 Mio. | 0,52 | 0,54% | 32,25 | 4,40 |
| 2019 [USD] | 5,41 Mrd. | 926,19 Mio. | 716,63 Mio. | 0,49 | 0,56% | 34,49 | 4,64 |
| 2018 [USD] | 5,30 Mrd. | 962,08 Mio. | 823,72 Mio. | 0,58 | 0,47% | 28,94 | 4,51 |
| 2017 [USD] | 4,75 Mrd. | 692,43 Mio. | 500,75 Mio. | 0,35 | 0,39% | 48,70 | 5,01 |
| 2016 [USD] | 4,37 Mrd. | 640,55 Mio. | 422,00 Mio. | 0,28 | 0,37% | 60,14 | 5,61 |
| 2015 [USD] | 4,46 Mrd. | 583,00 Mio. | 350,18 Mio. | 0,23 | 0,27% | 73,16 | 5,75 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der TERUMO CORP. Aktie
Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.